Celyad Oncology SA GAAP EPS of -$0.09

Celyad Oncology reported a GAAP Earnings Per Share (EPS) of -€0.09 for the first half of 2025, indicating financial losses during this period.

The company's net cash used for operational activities increased to €3.3 million in the first half of 2025, up from €2.8 million in the same period of 2024, driven by higher intellectual property expenses and costs associated with catheter development.

As of June 30, 2025, Celyad had €0.8 million in cash and cash equivalents, with no capital increase having occurred and the number of shares outstanding remaining at 41.4 million.

Recommendation Rating: Celyad Oncology Performance Overview

Celyad Oncology SA has released its financial results for the first half of 2025 (OTC:CLYYF). The company reported a GAAP Earnings Per Share (EPS) of -€0.09 for this period.

During the first half of 2025, Celyad used €3.3 million in net cash for its operational activities, reflecting a rise from €2.8 million in the corresponding period of 2024. This increase of €0.5 million was largely attributed to heightened global intellectual property (IP) activities and expenses related to catheter development.

As of June 30, 2025, the company held €0.8 million in cash and cash equivalents. Notably, there was no capital increase in the first half of 2025, and the total number of basic shares outstanding remained stable at 41.4 million, consistent with the figure reported on December 31, 2024.